Correlates of T-cell-mediated viral control and phenotype of CD8+ T cells in HIV-2, a naturally contained human retroviral infection

Blood

Volumn 121, Issue 21, 2013, Pages 4330-4339

  De Silva, Thushan I ^a,b,c   Peng, Yanchun ^b   Leligdowicz, Aleksandra ^a,b   Zaidi, Irfan ^a   Li, Lucy ^a   Griffin, Harry ^b   Blais, Marie Eve ^b   Vincent, Tim ^a,d   Saraiva, Mavinga ^a,d   Yindom, Louis Marie ^b   Van Tienen, Carla ^a   Easterbrook, Philippa ^e   Jaye, Assan ^a   Whittle, Hilton ^a,f   Dong, Tao ^b   Rowland Jones, Sarah L ^b  

^a Medical Research Council   (Gambia)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Iganga Mayuge Health and Demographic Surveillance Site   (Guinea-Bissau)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B4; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; ANTIRETROVIRUS AGENT; CD160 PROTEIN, HUMAN; CD244 PROTEIN, HUMAN; GAG PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; FLOW CYTOMETRY; GUINEA-BISSAU; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INFECTION CONTROL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIREMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-2; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; VIREMIA;

MLCS; MLOWN;

EID: 84880446868     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-472787     Document Type: Article

References (48)

1. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol. 2008; 16(12):588-595.
2. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654-657.
3. van der Loeff MF, Larke N, Kaye S, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.
4. Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS. 2007;21(3):317-324.
5. Hansmann A, Schim van der Loeff MF, Kaye S, et al. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1-and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr. 2005; 38(3):335-341.
6. Esbjörnsson J, Månsson F, Kvist A, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med. 2012;367(3):224-232.
7. Bertoletti A, Cham F, McAdam S, et al. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J Virol. 1998;72(3):2439-2448.
8. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995;1(1):59-64.
9. Duvall MG, Jaye A, Dong T, et al. Maintenance of HIV-specific CD41 T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol. 2006;176(11): 6973-6981.
10. Duvall MGPM, Precopio ML, Ambrozak DA, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008;38(2): 350-363.
11. Leligdowicz A, Yindom LM, Onyango C, et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest. 2007;117(10):3067-3074.
12. van Tienen C, Schim van der Loeff MF, Zaman SM, et al. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J Acquir Immune Defic Syndr. 2010;53(5): 640-647.
13. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1998;1(7):457-468.
14. Yindom LM, Leligdowicz A, Martin MP, et al. Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa. J Virol. 2010;84(16):8202-8208.
15. Dong T, Stewart-Jones G, Chen N, et al. HIVspecific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med. 2004; 200(12):1547-1557.
16. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79(2):167-174.
17. Holmgren B, Aaby P, Jensen H, Larsen O, da Silva Z, Lisse IM. Increased prevalence of retrovirus infections among older women in Africa. Scand J Infect Dis. 1999;31(5):459-466.
18. Brinkhof MW, Boulle A, Weigel R, et al; International Epidemiological Databases to Evaluate AIDS (IeDEA). Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6(4):e1000066.
19. Hersperger AR, Martin JN, Shin LY, et al. Increased HIV-specific CD81 T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood. 2011;117(14): 3799-3808.
20. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIVspecific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010;6(5):e1000917.
21. Appay V, Dunbar PR, Callan M, et al. Memory CD81 T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379-385.
22. Tussey LG, Nair US, Bachinsky M, et al. Antigen burden is major determinant of human immunodeficiency virus-specific CD81 T cell maturation state: potential implications for therapeutic immunization. J Infect Dis. 2003; 187(3):364-374.
23. Yamamoto T, Price DA, Casazza JP, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD81 T-cell exhaustion in HIV infection. Blood. 2011;117(18):4805-4815.
24. Jaffar S, Van der Loeff MS, Eugen-Olsen J, et al. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses. 2005;21(6):560-564.
25. Leligdowicz A, Feldmann J, Jaye A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis. 2010;201(1):114-122.
26. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD81 T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD41 cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92.
27. Chun TW, Justement JS, Sanford C, et al. Relationship between the frequency of HIVspecific CD81 T cells and the level of CD381 CD81 T cells in untreated HIV-infected individuals. Proc Natl Acad Sci USA. 2004;101(8): 2464-2469.
28. Pereyra F, Jia X, McLaren PJ, et al; International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010): 1551-1557.
29. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD81 T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13(1):46-53.
30. Buchbinder SP, Mehrotra DV, Duerr A, et al; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet. 2008; 372(9653):1881-1893.
31. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD81 T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007;204(10): 2473-2485.
32. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD81 T cells. Blood. 2006;107(12):4781-4789.
33. Chevalier MF, Jülg B, Pyo A, et al. HIV-1-specific interleukin-211 CD41 T cell responses contribute to durable viral control through the modulation of HIV-specific CD81 T cell function. J Virol. 2011; 85(2):733-741.
34. Zuñiga R, Lucchetti A, Galvan P, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol. 2006; 80(6):3122-3125.
35. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004;432(7018):769-775.
36. Matthews PC, Koyanagi M, Kløverpris HN, et al. Differential clade-specific HLA-B∗3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol. 2012;86(23):12643-12654.
37. Julg B, Williams KL, Reddy S, et al. Enhanced anti-HIV functional activity associated with Gagspecific CD8 T-cell responses. J Virol. 2010; 84(11):5540-5549.
38. Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, Miedema F. Persistent numbers of tetramer1 CD8(1) T cells, but loss of interferon-gamma1 HIV-specific T cells during progression to AIDS. Blood. 2002; 99(7):2505-2511.
39. Addo MM, Draenert R, Rathod A, et al. Fully differentiated HIV-1 specific CD81 T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE. 2007; 2(3):e321.
40. Sáez-Cirión A, Lacabaratz C, Lambotte O, et al; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA. 2007;104(16): 6776-6781.
41. Papagno L, Appay V, Sutton J, et al. Comparison between HIV-and CMV-specific T cell responses in long-term HIV infected donors. Clin Exp Immunol. 2002;130(3):509-517.
42. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD81 T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008;29(6): 1009-1021.
43. Papagno L, Spina CA, Marchant A, et al. Immune activation and CD81 T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2004; 2(2):E20.
44. Burgers WA, Riou C, Mlotshwa M, et al; CAPRISA 002 Acute Infection Study Team. Association of HIV-specific and total CD81 T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol. 2009;182(8):4751-4761.
45. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, Appay V. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS. 2007; 21(15):2005-2013.
46. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol. 2011;186(7): 4200-4212.
47. de Silva TI, Aasa-Chapman M, Cotten M, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol. 2012;86(2):930-946.
48. Leligdowicz A, Onyango C, Yindom LM, et al. Highly avid, oligoclonal, early-differentiated antigen-specific CD81 T cells in chronic HIV-2 infection. Eur J Immunol. 2010;40(7):1963-1972.